Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

273.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 84
Open 273.94
Bid (Size) 269.75 (1)
Ask (Size) 274.25 (1)
Prev. Close 273.94
Today's Range 273.94 - 273.94
52wk Range 211.71 - 329.72
Shares Outstanding N/A
Dividend Yield 3.11%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-7.89%
-7.89%
1 Month
-3.22%
-3.22%
3 Month
-12.93%
-12.93%
6 Month
+7.13%
+7.13%
1 Year
+14.67%
+14.67%

More News

Read More
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
Via The Motley Fool
How Is The Market Feeling About Amgen?
Via Benzinga
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Is Amgen Stock a Buy?
Via The Motley Fool
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
Via InvestorPlace
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Via Benzinga
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Via InvestorPlace
Exposures Product Safety
Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble
Via InvestorPlace
Topics Stocks
Exposures US Equities
7 Analysts Have This To Say About Amgen
Via Benzinga
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Via The Motley Fool
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Via InvestorPlace
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Via InvestorPlace
Amgen, Shell And More On CNBC's 'Final Trades'
Via Benzinga
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Via InvestorPlace
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
Via InvestorPlace
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
2 Biotech Stocks to Buy Hand Over Fist in April
Via The Motley Fool
3 Stocks to Consider Adding to Your Retirement Portfolio in April
Via The Motley Fool
Topics Retirement
Exposures Pension
Is Amgen The Rare Biotech With A Safe Dividend?
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.